Abstract
The amyloid-β (Aβ) peptides and in particular the longer, highly amyloidogenic isoform Aβ42 are believed by many to be the central disease-causing agents in Alzheimers disease (AD). Consequently, academic and pharmaceutical laboratories have focused on elucidating the mechanisms of Aβ production and developing strategies to diminish Aβ formation for treatment or prevention of AD. The most substantial advances have been made with respect to inhibitors of the γ-secretase enzyme, which catalyzes the final step in the generation of Aβ from the amyloid precursor protein (APP). Highly potent γ-secretase inhibitors which suppress production of all Aβ peptides are available today. However, due to the promiscuous substrate specificity of γ-secretase and its essential role in the NOTCH signaling pathway overt mechanismbased toxicity has been observed in preclinical studies of γ-secretase inhibitors. For that reason, specific blockage of Aβ42 production might be preferable over non-discriminatory γ-secretase inhibition but small molecule inhibitors of Aβ42 production have remained elusive until recently. This has changed with the discovery that certain non-steroidal antiinflammatory drugs (NSAIDs) including ibuprofen possess preferential Aβ42-lowering activity. These compounds seem to offer a window of modulation where Aβ42 production is potently inhibited whereas processing of the NOTCH receptor and other g-secretase substrates remains unaffected. The Aβ42-lowering activity of NSAIDs is not related to inhibition of cyclooxygenases and can be dissociated from the anti-inflammatory properties of this class of drugs. Ongoing efforts concentrate on uncovering the mechanism of action and improving potency and brain permeability of Aβ42-lowering compounds. Hopes are high that in the near future this will lead to the development of clinically viable compounds which selectively target Aβ42 as a key molecule in the pathogenesis of AD.
Keywords: amyloid precursor protein (APP), transmembrane domain (TMD), NOTCH signaling, NSAIDs, pro-inflammatory, Non-COX
Current Pharmaceutical Design
Title: Selective Modulation of Aβ42 Production in Alzheimers Disease: Non-Steroidal Anti-Inflammatory Drugs and Beyond
Volume: 12 Issue: 33
Author(s): Stefanie Leuchtenberger, Dirk Beher and Sascha Weggen
Affiliation:
Keywords: amyloid precursor protein (APP), transmembrane domain (TMD), NOTCH signaling, NSAIDs, pro-inflammatory, Non-COX
Abstract: The amyloid-β (Aβ) peptides and in particular the longer, highly amyloidogenic isoform Aβ42 are believed by many to be the central disease-causing agents in Alzheimers disease (AD). Consequently, academic and pharmaceutical laboratories have focused on elucidating the mechanisms of Aβ production and developing strategies to diminish Aβ formation for treatment or prevention of AD. The most substantial advances have been made with respect to inhibitors of the γ-secretase enzyme, which catalyzes the final step in the generation of Aβ from the amyloid precursor protein (APP). Highly potent γ-secretase inhibitors which suppress production of all Aβ peptides are available today. However, due to the promiscuous substrate specificity of γ-secretase and its essential role in the NOTCH signaling pathway overt mechanismbased toxicity has been observed in preclinical studies of γ-secretase inhibitors. For that reason, specific blockage of Aβ42 production might be preferable over non-discriminatory γ-secretase inhibition but small molecule inhibitors of Aβ42 production have remained elusive until recently. This has changed with the discovery that certain non-steroidal antiinflammatory drugs (NSAIDs) including ibuprofen possess preferential Aβ42-lowering activity. These compounds seem to offer a window of modulation where Aβ42 production is potently inhibited whereas processing of the NOTCH receptor and other g-secretase substrates remains unaffected. The Aβ42-lowering activity of NSAIDs is not related to inhibition of cyclooxygenases and can be dissociated from the anti-inflammatory properties of this class of drugs. Ongoing efforts concentrate on uncovering the mechanism of action and improving potency and brain permeability of Aβ42-lowering compounds. Hopes are high that in the near future this will lead to the development of clinically viable compounds which selectively target Aβ42 as a key molecule in the pathogenesis of AD.
Export Options
About this article
Cite this article as:
Leuchtenberger Stefanie, Beher Dirk and Weggen Sascha, Selective Modulation of Aβ42 Production in Alzheimers Disease: Non-Steroidal Anti-Inflammatory Drugs and Beyond, Current Pharmaceutical Design 2006; 12 (33) . https://dx.doi.org/10.2174/138161206778793029
DOI https://dx.doi.org/10.2174/138161206778793029 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Blocking Leukocyte Rolling: Does it have a Role in Disease Prevention?
Vascular Disease Prevention (Discontinued) Flavonoids, Breast Cancer Chemopreventive and/or Chemotherapeutic Agents
Current Medicinal Chemistry Synthesis and Endothelin Receptors Binding Affinity of New 1,3,5- Substituted Pyrrole-2-Carboxylic Acid Derivatives
Medicinal Chemistry Lipid Management and Peripheral Arterial Disease
Current Drug Targets Parvovirus B19 (B19V) Infection and Pregnancy
Current Pediatric Reviews Inflammatory Cardiovascular Risk Markers in Obstructive Sleep Apnoea Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Heart Failure Modulates the Muscle Reflex
Current Cardiology Reviews General or Local Anesthesia for TAVI? A Systematic Review of the Literature and Meta-Analysis
Current Pharmaceutical Design Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies
Recent Patents on Anti-Cancer Drug Discovery Fish and Apoptosis: Studies in Disease and Pharmaceutical Design
Current Pharmaceutical Design The Efficacy and Safety of Cilnidipine on Mild to Moderate Essential Hypertension: A Systematic Review and Meta-analysis of Randomized Controlled Trials in Chinese Patients
Cardiovascular & Hematological Disorders-Drug Targets Fibrinogen: A Predictor of Vascular Disease
Current Pharmaceutical Design Involvement of L-Carnitine in Cellular Metabolism: Beyond Acyl-CoA Transport
Mini-Reviews in Medicinal Chemistry A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases
Current Pharmaceutical Design A Journey into the World of Targeted Therapy: A Review of Gene Therapy, Stem Cell Therapy, and Cell Reprogramming in Cardiovascular Medicine
Recent Patents on Regenerative Medicine The Potential of 11C-acetate PET for Monitoring the Fatty Acid Synthesis Pathway in Tumors
Current Pharmaceutical Biotechnology Meet our Editorial Board Member
Cardiovascular & Hematological Agents in Medicinal Chemistry Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology Pathological Roles of Iron in Cardiovascular Disease
Current Drug Targets Cardiac Sarcolemmal Ion Channels and Transporters as Possible Targets for Antiarrhythmic and Positive Inotropic Drugs: Strategies of the Past-Perspectives of the Future
Current Pharmaceutical Design